Shares of GlaxoSmithKline plc (LON:GSK) have been assigned an average rating of “Hold” from the twenty-two ratings firms that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 1,590.53 ($21.30).

Several research firms have weighed in on GSK. Societe Generale restated a “sell” rating on shares of GlaxoSmithKline in a report on Thursday, November 9th. Berenberg Bank cut their price target on GlaxoSmithKline from GBX 1,835 ($24.57) to GBX 1,760 ($23.57) and set a “buy” rating for the company in a report on Thursday, November 2nd. Morgan Stanley set a GBX 1,450 ($19.42) price objective on GlaxoSmithKline and gave the company a “sell” rating in a research note on Monday, November 6th. Deutsche Bank set a GBX 1,610 ($21.56) price target on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Friday, October 27th. Finally, Barclays reaffirmed an “equal weight” rating and set a GBX 1,450 ($19.42) target price on shares of GlaxoSmithKline in a research report on Friday, October 27th.

In other news, insider Urs Rohner purchased 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The shares were bought at an average cost of GBX 1,518 ($20.33) per share, for a total transaction of £7,180.14 ($9,615.83). Also, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.45) per share, for a total transaction of £16,430.52 ($22,004.18). Over the last quarter, insiders have acquired 1,576 shares of company stock valued at $2,400,376.

GlaxoSmithKline (GSK) opened at GBX 1,296.84 ($17.37) on Friday. GlaxoSmithKline has a 12 month low of GBX 1,291.50 ($17.30) and a 12 month high of GBX 1,724.50 ($23.09).

GlaxoSmithKline (LON:GSK) last posted its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) EPS for the quarter, topping the consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The firm had revenue of GBX 784.30 billion for the quarter.

The company also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 9th. This represents a yield of 1.41%.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Receives Consensus Recommendation of “Hold” from Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/glaxosmithkline-plc-gsk-receives-consensus-recommendation-of-hold-from-brokerages-2.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.